These data indicate that the CancerVax vaccine may induce measurable and clinically relevant immune responses in patients with advanced colorectal cancer that correlate with survival. Dr. Morton is also the founder and a member of the Board of Directors of CancerVax Corporation. This novel therapeutic regimen for refractory colorectal cancer merits further investigation. CancerVax's therapeutic vaccine is an allogeneic, whole cell vaccine developed from three cell lines containing twenty known tumor-associated antigens. The maintenance phase follows with vaccine administration every four weeks for the remainder of the first year, every two months during Year Two, then every three months in Year Three and thereafter.
Colorectal cancer is one of the four most prevalent cancers worldwide.
Life expectancy for stage IV disease, which may affect as many as 50,000 individuals in the U.S. this year, is 7.5 months. Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.